INTERVIEW: TMS-for-depression pioneer Neuronetics readies for commercial ramp-up
This article was originally published in Clinica
Being first to market is not always what it’s cracked up to be, especially when your product is an innovative technology. Not only do you have to get the first adopters on board, there is also the issue of securing reimbursement to spur uptake of your product. The latter is particularly challenging when there is no existing code for your innovation and you need to create your own reimbursable market.
You may also be interested in...
The registry will collect data from more than 6,000 depression patients treated with transcranial magnetic stimulation at more than 100 different treatment facilities in the US to better understand how the therapy benefits patients in the "real world."
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.